Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics.[1] Bristol Myers Squibb acquired the company in January 2024.
History
Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[2] The inhibition to the mutation has shown to shrink the size of its tumors.[3] The company is based in San Diego, California. The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the Nasdaq[4] under the ticker symbol MRTX.[5]